Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) EBT (2016 - 2025)

Celldex Therapeutics has reported EBT over the past 16 years, most recently at -$81.3 million for Q4 2025.

  • Quarterly results put EBT at -$81.3 million for Q4 2025, down 72.68% from a year ago — trailing twelve months through Dec 2025 was -$258.8 million (down 63.91% YoY), and the annual figure for FY2025 was -$258.8 million, down 63.91%.
  • EBT for Q4 2025 was -$81.3 million at Celldex Therapeutics, down from -$67.0 million in the prior quarter.
  • Over the last five years, EBT for CLDX hit a ceiling of -$13.4 million in Q2 2021 and a floor of -$81.3 million in Q4 2025.
  • Median EBT over the past 5 years was -$34.3 million (2024), compared with a mean of -$37.1 million.
  • Biggest five-year swings in EBT: crashed 169.23% in 2022 and later grew 15.28% in 2023.
  • Celldex Therapeutics' EBT stood at -$20.1 million in 2021, then plummeted by 31.46% to -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then fell by 8.74% to -$47.1 million in 2024, then plummeted by 72.68% to -$81.3 million in 2025.
  • The last three reported values for EBT were -$81.3 million (Q4 2025), -$67.0 million (Q3 2025), and -$56.6 million (Q2 2025) per Business Quant data.